News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sanofi (France) (SAN.PA) Says Zaltrap Cancer Drug Study Positive


10/8/2012 7:52:46 AM

French drug giant Sanofi S.A. (SNY: Quote) on Monday said the detailed positive results from the pivotal Phase III VELOUR study evaluating ZALTRAP (aflibercept) Injection for Intravenous Infusion for patients with previously treated metastatic colorectal cancer were published in the October 2012 edition of the Journal of Clinical Oncology or JCO. The company said the latest data supported the regulatory approval of ZALTRAP by the U.S. Food and Drug Administration on August 3 after a Priority Review. ZALTRAP is a recombinant fusion protein that binds to Vascular Endothelial Growth Factor or VEGF- A, VEGF-B, and placental growth factor. Sanofi and Regeneron Pharmaceuticals, Inc. (REGN: Quote) share equally the global profits of ZALTRAP.

Read at RTT News
Read at Reuters
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES